Heart failure & cardiomyopathies
Patient Eligibility for Established and Novel Guideline-Directed Medical Therapies After Acute Heart Failure Hospitalization
Authors' conclusion
The majority of patients admitted with AHF are eligible for foundational quadruple therapy and additional novel medications across a spectrum of HF phenotypes.
Study context
- Population
- Patients discharged alive after acute heart failure (AHF) admission with documented left ventricular ejection fraction (LVEF), CAN-HF registry, January 2017–April 2020284 de novo, 525 chronic heart failure (HF)
- Participants
- 809 patients
- Exposure
- Heart failure with reduced ejection fraction (HFrEF) vs heart failure with preserved ejection fraction (HFpEF)
- HFrEFn = 455
- HFpEFn = 354
- Outcome
- Eligibility for initiation of GDMT and newer HF agents (guidelines or recent trial enrolment criteria)
Methodological detailsCAN-HF registry
- CAN-HF registry
Main finding
As reported in the abstract
Eligibility for therapies
| Group | ARNI | Beta-blockers | MRA | SGLT2 inhibitors | Ivabradine | Vericiguat (trial criteria) | Omecamtiv mecarbil (trial criteria) | Foundational quadruple therapy | ARNI (trial criteria) | SGLT2 inhibitors (trial criteria) |
|---|---|---|---|---|---|---|---|---|---|---|
| HFrEF | 73.6% | 94.9% | 84.4% | 81.1% | 15.6% | 25.9% | 30.1% | 71.6% | ||
| HFpEF | 37.6% | 59.9% |
ARNI
HFrEF73.6%
HFpEF— not stated in the abstract
Beta-blockers
HFrEF94.9%
HFpEF— not stated in the abstract
MRA
HFrEF84.4%
HFpEF— not stated in the abstract
SGLT2 inhibitors
HFrEF81.1%
HFpEF— not stated in the abstract
Ivabradine
HFrEF15.6%
HFpEF— not stated in the abstract
Vericiguat (trial criteria)
HFrEF25.9%
HFpEF— not stated in the abstract
Omecamtiv mecarbil (trial criteria)
HFrEF30.1%
HFpEF— not stated in the abstract
Foundational quadruple therapy
HFrEF71.6%
HFpEF— not stated in the abstract
ARNI (trial criteria)
HFrEF— not stated in the abstract
HFpEF37.6%
SGLT2 inhibitors (trial criteria)
HFrEF— not stated in the abstract
HFpEF59.9%
Observational data: associations, not effects.
Further findings
Eligibility for foundational quadruple therapy in HFrEF, by presentation (subgroup)
Original publication
Patient Eligibility for Established and Novel Guideline-Directed Medical Therapies After Acute Heart Failure Hospitalization. JACC Heart Fail. Published 11 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →